Search Within

Patricia Myskowski

Formats
  1. Journal Article (121)
  2. Meeting Abstract (72)
  3. Book Section (8)
  4. Research Letter (6)
  5. Review (5)
  6. Conference Paper (2)
  7. Correspondence (2)
  8. Editorial (2)
Groups
  1. Department of Medicine (218)
  2. Dermatology (218)
  3. Dermatology Service (218)
  4. Division of Subspecialty Medicine (218)
  5. Population Sciences Research Program (90)
  6. Department of Pathology and Laboratory Medicine (87)

More Groups

People
  1. Steven Horwitz (75)
  2. Melissa Pulitzer (60)
  3. Alison Moskowitz (57)
  4. Shamir Geller (43)
  5. Christiane Querfeld (21)
  6. Klaus Busam (21)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (5)
  4. 2022 (3)
  5. 2021 (9)
  6. 2020 (11)

More Years

Publications
  1. Journal of the American Academy of Dermatology (37)
  2. Blood (25)
  3. Journal of Investigative Dermatology (13)
  4. Clinical Research (9)
  5. International Journal of Dermatology (9)
  6. Journal of Clinical Oncology (9)

More Publications

Publishers
  1. Mosby Elsevier (37)
  2. American Society of Hematology (25)
  3. Wiley Blackwell (23)
  4. Elsevier Inc. (14)
  5. Elsevier Science, Inc. (14)
  6. Lippincott Williams & Wilkins (13)

More Publishers

Results (218)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RAS mutation analysis of transformed mycosis fungoides identifies a KRAS G13D mutation
    Meeting Abstract

    Connolly, B. M.; Hedvat, C.; Myskowski, P. L.; Horwitz, S. M.; Pulitzer, M. P.
    Modern Pathology (2012)

    Fulltext@MSK | Save
  • RAS mutation analysis of transformed mycosis fungoides identifies a KRAS G13D mutation
    Meeting Abstract

    Connolly, B. M.; Hedvat, C.; Myskowski, P. L.; Horwitz, S. M.; Pulitzer, M. P.
    Laboratory Investigation (2012)

    Fulltext@MSK | Save
  • Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations
    Journal Article

    Mehta, N.; Wayne, A. S.; Kim, Y. H.; Hale, G. A.; Alvarado, C. S.; Myskowski, P.; Jaffe, E. S.; Busam, K. J.; Pulitzer, M.; Zwerner, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2012)

    Fulltext@MSK | Save
  • Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
    Journal Article

    Balagula, Y.; Huston, K. B.; Busam, K. J.; Lacouture, M. E.; Chapman, P. B.; Myskowski, P. L.
    Investigational New Drugs (2011)

    Fulltext@MSK | Save
  • Pigmentary changes in a patient treated with imatinib
    Journal Article

    Balagula, Y.; Pulitzer, M. P.; Maki, R. G.; Myskowski, P. L.
    Journal of Drugs in Dermatology (2011)

    Fulltext@MSK | Save
  • Keratoacanthomas associated with imatinib mesylate
    Journal Article

    Balagula, Y.; Busam, K. J.; Carvajal, R. D.; Wolchok, J. D.; Myskowski, P. L.
    Acta Oncologica (2011)

    Fulltext@MSK | Save
  • Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
    Journal Article

    Balagula, Y.; Garbe, C.; Myskowski, P. L.; Hauschild, A.; Rapoport, B. L.; Boers-Doets, C. B.; Lacouture, M. E.
    International Journal of Dermatology (2011)

    Fulltext@MSK | Save
  • Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL)
    Meeting Abstract

    Straus, D. J.; Duvic, M.; Horwitz, S. M.; Hymes, K. B.; Goy, A.; Hernandez-Ilizaliturri, F. J.; Feldman, T.; Wegner, B.; Myskowski, P.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Dermatological toxicities associated with MEK 1/2 inhibitor AZD6244
    Meeting Abstract

    Myskowski, P.; Balagula, Y.; Barth, K.; Busam, K.; Lacouture, M. E.; Chapman, P. B.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Hematopoietic neoplasms
    Book Section

    Junkins-Hopkins, J. M.; Myskowski, P. L.; Busam, K. J.
    In Busam, K. J. (Eds.) Dermatopathology (2010)

    Fulltext@MSK | Save